|
|
Vaccine Detail
|
PEP-3-KLH Conjugate Vaccine |
| Vaccine Information |
- Vaccine Ontology ID: VO_0007096
- Type: Conjugate vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- EGFR
gene engineering:
- Preparation: PEP-3, a 13-amino acid peptide with a terminal cysteine (LEEKKGNYVVTDHC) that spans the EGFRvIII mutation was conjugated to KLH at a 1:1 ratio (w/w) and used for immunization (Heimberger et al., 2003).
- Description: This is for Melanoma Cancer (NCT00626015). A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC) (Heimberger et al., 2003; NCIT_C74070).
|
| Host Response |
|
|
| References |
Heimberger et al., 2003: Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(11); 4247-4254. [PubMed: 14519652].
NCIT_C74070: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74070]
NCT00626015: [https://clinicaltrials.gov/ct2/show/NCT00626015?term=PEP-3-KLH&rank=1]
|
|
